Our clinical trials program is bringing the world’s best treatments to patients with eye diseases.
Protocol Number: CMOAPEYE0438
Phase: IV
Sponsor: Allergan
Information: Phase IV, open label, non randomised, prospective study of ozurdex in the treatment of diabetic macular oedema
Protocol Number: RTA255-P001
Phase: IV
Sponsor: Alcon Research
Information: Assessment of anatomical and functional outcomes in patients treated with ocriplasmin for vitreomacular traction/symptomatic vitreomacular adhesion
Protocol Number: RFB002A2406
Phase: Observational
Sponsor: Novartis
Information: Study to observe the effectiveness and safety of ranibizumab through individualized patient treatment and associated outcomes
Protocol Number: CRFB002AAU17
Phase: IV
Sponsor: Novartis
Information: Development of new geographic atrophy in patients with neovascular (wet) age-related macular degeneration: a comparison of ranibizumab and aflibercept
Protocol Number: GX29185
Phase: III
Sponsor: F. Hoffmann-La Roche
Information: A phase III, multicentre, randomised, double-masked, sham-controlled study to assess the safety and efficacy of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration